Skip to main content
. 2014 Apr 18;8(7):1231–1239. doi: 10.1016/j.molonc.2014.03.016

Figure 4.

Figure 4

Anti‐CCL2 sensitizes s.c. OVCAR‐3/TP to carboplatin. Measurement of total body tumor burden over time for animals bearing OVCAR‐3/TP GFP/luc+ tumors as measured with caliper and by BLI photon counts. Normalized mean ± SEM is shown for each group. A and B. Animals representing four out of the six treatment groups are shown. Mice were treated for 5 weeks with carboplatin once a week from weeks 2 to 7 at 100 mg/kg, and anti‐CCL2 mAbs at 20 mg/kg twice a week for 8 weeks from weeks 2 to 10. C and D. Animals representing the six treatment groups are shown. Mice were treated for 4 weeks between weeks 6 and 10 with 80 mg/kg of carboplatin once a week and with 20 mg/kg of CCL2 mAbs twice a week.